Search
crisaborole (Eucrisa)
FDA-approval Dec 2016
Indications:
- atopic dermatitis*
* complete or near complete clearance in 1/3 of patients within 1 month [2]
Dosage:
- ointment applied topically twice daily
Adverse effects:
- pain, burning, stinging at sit of application
- hypersensitivity reactions
Mechanism of action:
- phosphodiesterase-4 inhibitor
Notes:
- manufactured by Palo Alto, California-based Anacor Pharmaceuticals, Inc.
General
phosphodiesterase-4 inhibitor
heterocyclic compound, 2 rings
aromatic compound
topical agent
Database Correlations
PUBCHEM cid=44591583
References
- Brown T
FDA Approves Crisaborole (Eucrisa) for Atopic Dermatitis.
Medscape. Dec 14, 2016.
http://www.medscape.com/viewarticle/873305
- FDA News Release. December 14, 2016
FDA approves Eucrisa for eczema.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm
- Bankhead C
MedPageToday. March 7, 2017
American Academy of Dermatology (AAD) Meeting Coverage.
Studies Confirm Efficacy of Topical PDE4 Inhibitor -
Significant improvement in atopic dermatitis within a week
https://www.medpagetoday.com/MeetingCoverage/AAD/63654
- Fowler JF, et al.
Crisaborole ointment improves global atopic dermatitis severity:
Pooled results from two phase III clinical trials.
American Academy of Dermatology (AAD 2017). Abstract 5667.